Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — Q4 FY26 Earnings Presentation
17 slides from Viyash Scientific's earnings presentation, May 19, 2026
Slide 1: Viyash Scientific Limited filing cover letter
Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E: investorrelations@viyash.com
Slide 2: Investor Presentation Q4 FY26
INVESTOR PRESENTATION Q4 FY26 V I YA S H S C I E N T I F I C L I M I T E D May 19, 2026 1
Slide 3: Steadfast commitment to improvement in business fundamentals
Steadfast commitment to improvement in business fundamentals “Fiscal Year 2026 has been a transformative year for Viyash Scientific, marked by the successful integration of our facilities, operations, and corporate functions into one unified platform. Q4 was the strongest quarter in the Company’s hi
Slide 4: Q4FY26 Financial Snapshot
Q4FY26 Financial Snapshot 3 Notes: 1. EBITDA are adjusted for ESOP costs
Slide 5: Viyash Scientific: Q4 FY26 Performance Highlights
Viyash Scientific : Q4 FY26 Performance Highlights All values in ₹ Mn Revenues EBITDA¹ EBITDA Margin Net Debt to LTM EBITDA¹ ₹9,200 ₹2,001 21.7% 0.2x Million Million Net Debt- ₹ 1661 Mn +19.1% +63.8 % +590 bps 1.0x YoY YoY YoY in FY25 Net Debt - ₹ 4,511 4 Notes: 1. EBITDA are adjusted for ESOP costs
Slide 6: Viyash: FY26 Performance Highlights
Viyash : FY26 Performance Highlights All values in ₹ Mn Revenues EBITDA¹ EBITDA¹ Margin Net Debt to LTM EBITDA¹ ₹34,203 ₹7,025 20.5% 0.2x Million Net Debt- ₹ 1661 Mn Million +13.8% +59.6 % +590 bps 1.0x YoY YoY YoY in FY25 Net Debt - ₹ 4,511 5 Notes: 1. EBITDA are adjusted for ESOP costs
Slide 7: Revenue Performance Key highlights
Revenue Performance Key highlights All values in ₹ Mn Q4 Q3 12M Revenue Distribution FY26 FY25 YoY % FY26 QnQ % FY26 FY25 YoY % Formulations 4,991 3,893 28% 4,809 4% 18,657 15,828 18% Europe 1,733 1,365 27% 1,790 -3% 6,682 5,614 19% Emerging Markets 1,725 1,429 21% 1,630 6% 6,305 5,142 23% India 379
Slide 8: Sustained Sales Growth with Consistent EBITDA Expansion
7 Sustained Sales Growth with Consistent EBITDA Expansion All values in ₹ Mn SALES GROSS MARGIN 5,071 9,500 9,200 5,000 4,718 4,675 9,000 65.0% 8,503 8,584 4,111 3,971 4,075 8,500 3,741 7,916 4,000 3,580 8,000 7,740 7,723 55.5% 54.5% 55.1% 55.0% 52.8% 51.9% 51.2% 51.3% 7,500 7,292 7,313 49.1% 3,000
Slide 9: Viyash Consolidated Financials
Viyash Consolidated Financials All values in ₹ Mn Q4 Q4 Grw Q3 Grw Grw Particulars FY26 FY25 FY26 FY25 YoY % FY26 QnQ % YoY % Revenue from Operations 9,200 7,723 19.1% 8,584 7.2% 34,203 30,068 13.8% Material Consumption (4,128) (3,648) (3,909) (15,627) (14,702) Gross Margin 5,071 4,075 24.4% 4,675 8
Slide 10: Business Update
Viyash Business Update
Slide 11: Key Highlights from Q4 FY26
Key Highlights from Q4 FY26 Facility Inspections Regulatory Approvals Launches 2 Regulatory Audits 4APIs: (USDMF-1 ; 5 APIs (2-USA, 2- 36 Customer audits EDQM-1; JDMF-1, MENA, 1- CA) ANVISA-1) 1 FDF (USA) 4 FDFs- USFDA Products Filed Validations Completed R&D Pipeline 4 APIs – USDMF (2), 6 APIs 19 P
Slide 12: FY26: Further strengthened formulation business
FY26: Further strengthened formulation business o Europe o Renewed EUGMP certification for Spanish manufacturing plant o Good business performance, led by Exports & Companion Animal Segment o Partnered with VetViva Richter for Canine Heart therapy o Initiated direct companion animal sales activities
Slide 13: Merger Update
Viyash Merger Update
Slide 14: Merger process status update
Merger – Process Update Merger process status update • Merger has been approved by all regulatory authorities, and the merger is in effect • Focus on synergy realization for next 12 months • The process is well on track as per estimated timelines 13
Slide 15: Synergy Update
Synergy Update Area Key Ideation Action Items Progress API R&D fully integrated leading to accelerated development • R&D teams to be co-located; projects to be ideated on • 6 New animal health products NPD & cost improvement Regulatory filing R&D developed/validated • QA & Testing movement to on-sit
Slide 16: For details, feel free to contact
For details, feel free to contact: Yoshita Vora Abhishek Singhal Company Secretary Investor Relations Consultant +91 22 4111 4777 abhishek@arunya.co.in investorrelations@viyash.com Registered Office: Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 50008
Slide 17: Thank You
Thank You Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India info@viyash.com | www.viyash.com Copyright © 2021. Viyash. All Rights Reserved.